Program
lofexidine
Also written as “Lofexidine HCl”, “Lofexidine” and “Lofexidine hydrochloride”.
Its studies are mostly in Opioid-Related Disorders · Liver Failure · Kidney Failure, Chronic, led by USWM, LLC (dba US WorldMeds).
Furthest: phase 3, since May 22, 201315 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| USWM, LLC (dba US WorldMeds) | 150 open or running | phase 3since May 22, 2013 | Mar 4, 2011 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 1 study since Mar 4, 2011.
- Sep 13, 2011Phase 1 study in HealthyNCT01437306 · 13 enrolled · United States
- Feb 14, 2012Phase 1 study in Opioid-Related DisordersNCT01558934 · 6 enrolled · United States
- Jun 14, 2012Phase 1 study in Normal Healthy VolunteersNCT01629446 · 6 enrolled · United States
- Jul 9, 2012Phase 1 study in Opioid-Related DisordersNCT01650649 · 27 enrolled · United States
- Mar 25, 2013Phase 1 study in Opioid-Related DisordersNCT01820442 · 30 enrolled · United States
- May 22, 2013Phase 3 study in Opioid-Related DisordersNCT01863186 · 603 enrolled · United States
- Jul 29, 2014Phase 1 study in Liver FailureNCT02318836 · 24 enrolled · United States
- Dec 5, 2014Phase 1 study in Kidney Failure, ChronicNCT02313103 · 16 enrolled · United States
- Feb 9, 2015Phase 3 study in Opioid WithdrawalNCT02363998 · 286 enrolled · United States
- May 7, 2015Phase 1 study in HealthyNCT02446002 · 25 enrolled · United States
- Feb 1, 2016Phase 1 study in HealthyNCT02681198 · 24 enrolled · United States
- Jul 2, 2019Phase 2 study in Opioid Withdrawal (Disorder)NCT04070157 · 4 enrolled · United States
- Nov 25, 2019Phase 1 study in Normal Healthy VolunteersNCT04188730 · 16 enrolled · United States
- Nov 19, 2024Phase 1 study in Opioid-Related DisordersNCT06711640 · United States
TargetBeta
“Adrenergic receptor alpha-2 agonist”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| brimonidinerule | AbbVie | phase 4 | 54 |
| Dexmedetomidinerule | Pfizer | phase 4 | 46 |
| Oxymetazolinerule | AbbVie | phase 4 | 20 |
| Phentolaminerule | opus-genetics-inc | phase 4 | 18 |
| Epinephrinerule | nasus-pharma | phase 4 | 17 |
| tizanidinerule | Teva Pharmaceutical Industries | phase 4 | 11 |
| Clonidinerule | pharmafina | phase 4 | 5 |
Studies
All 15 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06711640Opioid-Related Disorders · United States | 1 | Withdrawn | Jan 2026 | 0 |
| NCT04188730Normal Healthy Volunteers · United States | 1 | Completed | Mar 26, 2021 | 16 |
| NCT04070157Opioid Withdrawal (Disorder) · United States | 2 | Terminated | Nov 27, 2019 | 4 |
| NCT02681198Healthy · United States | 1 | Completed | Mar 2016 | 24 |
| NCT02446002Healthy · United States | 1 | Completed | Jun 2015 | 25 |
| NCT02363998Opioid Withdrawal · United States | 3 | Completed | Sep 2015 | 286 |
| NCT02313103Kidney Failure, Chronic · United States | 1 | Completed | Feb 2015 | 16 |
| NCT02318836Liver Failure · United States | 1 | Completed | Oct 2014 | 24 |
| NCT01863186Opioid-Related Disorders · United States | 3 | Completed | Nov 2014 | 603 |
| NCT01820442Opioid-Related Disorders · United States | 1 | Completed | Sep 2013 | 30 |
| NCT01650649Opioid-Related Disorders · United States | 1 | Completed | Dec 2012 | 27 |
| NCT01629446Normal Healthy Volunteers · United States | 1 | Completed | Jun 2012 | 6 |
| NCT01558934Opioid-Related Disorders · United States | 1 | Completed | Apr 2012 | 6 |
| NCT01437306Healthy · United States | 1 | Completed | Oct 2011 | 13 |
| NCT01310296Normal Healthy Volunteers Will be Treated With Lofexidine to Understand the Absolute Bioavailability and Mass Balance Recovery of the Product · United States | 1 | Completed | Aug 2011 | 12 |
How it is read
Names in the registry
- “Lofexidine HCl”, 5 entries
- “Lofexidine”, 3 entries
- “Lofexidine hydrochloride”, 3 entries
- “LUCEMYRA (lofexidine) tablets”, 1 entry
- “Lofexidine (granules for reconstitution)”, 1 entry
Conditions, from the studies’ own filings
- Opioid-Related Disorders, 5 studies
- Liver Failure, 1 study
- Kidney Failure, Chronic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.